The effects of the competitive NMDA receptor antagonist CPP on the high pressure neurological syndrome in a primate model

The neurophysiological interactions between the high pressure neurological syndrome (HPNS) and a new beta carboline, abecarnil, were studied in the non-human primate Papio anubis. Abecarnil is a partial agonist at the benzodiazepine site on the GABA/benzodiazepine receptor. Six animals were exposed on two occasions to pressures of 91 ATA in an environment of helium and oxygen. One exposure was pretreated with a total dose of abecarnil 1.0 mg/kg, the other with an equivalent volume of vehicle. Treatment with abecarnil prevented the severe signs of HPNS occurring between 51 and 91 ATA. Onset pressures of the various signs were unaffected. Some signs, e.g. myoclonus, became more frequent when abecarnil was used. A residual protective effect of abecarnil was present 4 weeks after the dose was given, active at pressures less than 71 ATA. Changes with pressure in the EEG were recorded primarily from the frontal cortex, but were also present in the parietal and occipital areas of the left cortex. Amplitude and frequency spectra were calculated and changes with pressure in the four conventional wavebands, plus two others, analysed. The most striking change was the prevention by abecarnil of the pressure-induced 100% increase in alpha wave amplitude in the frontal region. It is concluded that modulation of GABA transmission is important in controlling the expression of HPNS.

show abstract

Interactions of theβ carboline abecarnil with the high pressure neurological syndrome in a primate model

Pearce

Halsey

Maclean

et al. 1992

Psychopharmacology

View full text Add to dashboard Cite

show abstract

The orally active NMDA receptor antagonist CGP 39551 ameliorates the high pressure neurological syndrome inPapio anubis

Pearce¹,

Halsey²,

Maclean³

et al. 1993

Brain Research

View full text Add to dashboard Cite

Strychnine-insensitive glycine site antagonists attenuate a cardiac arrest-induced movement disorder

Matsumoto¹,

Nguyen²,

Truong³

1995

European Journal of Pharmacology

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

The effects of the competitive NMDA receptor antagonist CPP on the high pressure neurological syndrome in a primate model

Cited by 11 publications

References 18 publications

Interactions of theβ carboline abecarnil with the high pressure neurological syndrome in a primate model

Interactions of theβ carboline abecarnil with the high pressure neurological syndrome in a primate model

The orally active NMDA receptor antagonist CGP 39551 ameliorates the high pressure neurological syndrome inPapio anubis

Strychnine-insensitive glycine site antagonists attenuate a cardiac arrest-induced movement disorder

Contact Info

Product

Resources

About